Syndax Pharmaceuticals, Inc.
SNDX
$10.99
$0.292.71%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -331.20M | -318.76M | -297.06M | -264.08M | -240.63M |
| Total Depreciation and Amortization | 5.00K | 8.00K | 11.00K | 12.00K | 12.00K |
| Total Amortization of Deferred Charges | 142.00K | 30.00K | -- | -- | -- |
| Total Other Non-Cash Items | 32.23M | 30.55M | 26.09M | 21.82M | 19.83M |
| Change in Net Operating Assets | 12.31M | 13.27M | 12.09M | 1.05M | 15.87M |
| Cash from Operations | -286.52M | -274.90M | -258.86M | -241.20M | -204.92M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -26.23M | -219.78M | 32.91M | -13.86M | -1.71M |
| Cash from Investing | -26.23M | -219.78M | 32.91M | -13.86M | -1.71M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.48M | 9.72M | 264.43M | 263.18M | 263.83M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 343.65M | 343.65M | -- | -- | -- |
| Cash from Financing | 352.13M | 353.37M | 264.43M | 263.18M | 263.83M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39.38M | -141.31M | 38.47M | 8.12M | 57.20M |